NCT06830889招募中3 期
A Randomized Controlled Phase Ill Clinical Study of BL-M07D1 for Injection Versus Trastuzumab Emtansine (T-DM1) in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 1,450
- 试验地点
- 2
- 主要终点
- Invasive Disease-free Survival (IDFS)
研究概览
简要总结
This trial is a registered phase III, randomized, open-label, multicenter study designed to evaluate the efficacy and safety of BL-M07D1 in the adjuvant treatment of HER2-positive breast cancer with residual invasive cancer after neoadjuvant therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Sign the informed consent form voluntarily and follow the protocol requirements;
- •Women aged ≥18 years and ≤75 years at the time of written informed consent;
- •Expected survival time ≥6 months;
- •Patients with histologically confirmed HER2-positive invasive breast cancer;
- •Before neoadjuvant therapy, the clinical TNM staging was T1-4, N0-3, M0 (excluding T1N0) based on the 8th edition of the American Joint Committee on Cancer (AJCC) staging system;
- •The presence of residual invasive cancer confirmed by postoperative pathological examination must meet one of the conditions specified in the protocol;
- •Previous neoadjuvant therapy should meet the prescribed treatment conditions;
- •Had received radical mastectomy;
- •Determine hormone receptor (HR) status;
- •The interval between radical surgery and randomization was at least 3 weeks and at most 12 weeks;
- •ECOG score 0 or 1;
- •The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0;
- •No blood transfusion within 14 days before the first use of the study drug and no use of colony-stimulating factors were allowed;
- •For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before starting treatment, serum pregnancy must be negative, and the patient must not be lactating; All enrolled patients should use adequate and highly effective contraception during the entire treatment cycle and for 7 months after the end of treatment.
排除标准
- •A diagnosis of stage IV metastatic breast cancer was made;
- •Bilateral breast cancer;
- •Any previous history of breast cancer (unilateral or contralateral) except for lobular carcinoma in situ (LCIS);
- •Evidence of clinically significant residual disease or recurrent or metastatic disease after neoadjuvant therapy and surgery;
- •Other primary malignancies diagnosed within 5 years before the first dose;
- •Received previous HER2-ADC, immunotherapy, or other antitumor biological therapy;
- •Subjects are participating in other clinical studies and receiving anti-tumor treatment;
- •Prior treatment with anthracyclines, doxorubicin equivalent cumulative dose > 240 mg/m2; Cumulative dose of epirubicin or liposomal doxorubicin hydrochloride > 480 mg/m2;
- •History of severe cardiovascular or cerebrovascular disease within six months before screening;
- •QT prolongation, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia;
- •Poorly controlled hypertension (systolic blood pressure > 150 mmHg or diastolic blood pressure > 100 mmHg);
- •Complicated with pulmonary diseases leading to severe impairment of lung function;
- •A history of ILD/interstitial pneumonia requiring steroid therapy, current ILD/interstitial pneumonia, or suspected such disease during screening; CTCAE v5.0 was used to define grade ≥3 pulmonary disease and grade ≥2 radiation pneumonitis;
- •Human immunodeficiency virus antibody (HIVAb) positive, active hepatitis B virus infection, liver cirrhosis, or hepatitis C virus infection;
- •Had a serious infection within 4 weeks before the first dose of study drug; There was active pulmonary inflammation at the time of screening;
- •Were receiving > within 2 weeks before the first dose; 10mg/d prednisone systemic corticosteroids or equivalent anti-inflammatory active drugs or any form of immunosuppressive therapy;
- •Patients with a history of severe allergy to recombinant humanized antibodies or to any of the excipents of BL-M07D1;
- •Known hypersensitivity or delayed hypersensitivity to certain components of T-DM1 or similar drugs, or known contraindications to T-DM1;
- •Had a history of autologous or allogeneic stem cell transplantation or organ transplantation;
- •Have a severe neurological or psychiatric illness;
- •Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing the informed consent;
- •Intestinal obstruction, Crohn's disease, ulcerative colitis or chronic diarrhea;
- •Subjects scheduled to receive live vaccine or within 28 days before the first dose;
- •Patients with other serious physical and laboratory abnormalities or poor adherence that may increase the risk of participating in the study, or interfere with the results of the study, and patients who were deemed by the investigators to be unsuitable for participation in the study.
研究组 & 干预措施
BL-M07D1
Experimental
Participants receive BL-M07D1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
干预措施: BL-M07D1 (Drug)
T-DM1
Active Comparator
Participants receive T-DM1 as intravenous infusion for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
干预措施: T-DM1 (Drug)
结局指标
主要结局
Invasive Disease-free Survival (IDFS)
时间窗: Up to approximately 77 months
IDFS refers to the absence of invasive cancer recurrence after breast cancer treatment.
次要结局
- Disease-free Survival(DFS)(Up to approximately 77 months)
- Distant Recurrence-free Interval (DRFI)(Up to approximately 77 months)
- Overall Survival (OS)(Up to approximately 77 months)
- Treatment Emergent Adverse Event (TEAE)(Up to approximately 77 months)
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
不适用
A Phase ?randomized controlled cllinical trial of carboplatin and paclitaxel(OR GEMCITABINE) alone or incombination with bevacizumab (NSC #704865, IND #113912) followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and follopian tube cancerKCT0003484Seoul National University Hospital1,052
招募中
2 期
A Randomized Controlled Phase II Clinical Trial with Intradermal IMO-2125 (Tilsotolimod) in pT3-4 cN0M0 Melanomaskin cancerMelanomaNL-OMON52549Vrije Universiteit Medisch Centrum214
尚未招募
不适用
A clinical trial to investigate immunotherapy (IMO-2125) in the skin of patients with a melanoma which is at least 2 millimeters thickNL-OMON26696VU University medical center214
已完成
Unknown
Comparing Two Different Regional Anaesthetic Techniques With Standard IV Analgesic Technique For Post-Operative Pain Management In Patients Undergoing Laproscopic Cholecystectomy.CTRI/2023/03/050416ABHINAV NANDA111
已完成
2 期
The Impact of Social Cognition Training and Oxytocin on Social Functioning in Early Psychosis.ACTRN12612000190808The University of Sydney50